Navigation Links
Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Date:6/2/2008

ing the clinical safety endpoints. There were no observed clinically relevant adverse events associated with the treatment at all the concentrations (0 to 40 mg of SL017) and light doses (10 to 20 joules/cm(2)) administered. The light treatment, conveniently administered in a dermatology clinic, was well tolerated. The therapeutic potential of SL017 was evidenced by the expected (PDT) effects, such as redness, edema, occasional blisters, stinging and burning. The clinical correlates of dyskeratosis and inflammation were likewise appropriately noted on skin biopsy. Clinical and pathological results correlated very well, and conformed not only to the expected effects of PDT but also to the dosage of the drug and light energy administered. The study suggests that a 2% topical formulation of SL017 and a fluence of 20 joules/cm (2) provide expected PDT outcomes. Importantly, this Phase I study did not identify any safety concerns with respect to the parameters evaluated at the dosages of drug and light employed.

"I am encouraged by the confirmation of the topical PDT effects of SL017 and its potential for future applications in a variety of dermatological conditions including Actinic Keratosis," commented Dr. Gilles Lauzon, former Director, Division of Dermatology, University of Alberta and one of the investigators of the study.

The potential applications of cutaneous PDT also include acne, rosacea, superficial skin cancers, cutaneous T-cell lymphoma, localized scleroderma, warts, leishmaniasis and skin rejuvenation. Quest has already shown the follicular uptake of SL017 in humans; and is currently conducting a 90-patient trial addressing potential hair removal applications with results anticipated by end of this year. The Company is also evaluating the utility of SL017 for the treatment of acne in a preclinical model.

Paramount Biosciences, a global pharmaceutical and healthcare investment firm, has exclusive rights to develop and commercialize SL01
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... made as distribution channel reorders,continue, FREDERICK, ... maker of ActiPatch(R) Therapy, the drug free ... delivering continuous pulse,therapy that revolutionizes the way ... distribution penetration into the Canadian market.,ActiPatch Therapy ...
... Consultancy for Emerging Chinese Companies, HAIKOU CITY, ... Inc. ("China Pharma") (OTC Bulletin Board: CPHI),which develops, ... China, today announced the appointment of,The Ruth Group ... Zhilin Li, President and CEO of China Pharma ...
... BURLINGAME, Calif., Oct. 21 Sensorin, which ... measurement,platform for bioprocess applications, today announced the ... Use of proceeds from the financing includes,product ... proprietary pH,sensing system. Terms of the financing ...
Cached Biology Technology:BioElectronics Announces Significant Progress in Canadian and International Distribution 2China Pharma Holdings, Inc. Appoints The Ruth Group 2China Pharma Holdings, Inc. Appoints The Ruth Group 3Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bacteria hijack plentiful iron supply source to flourish 2
... engineers, led by the University of Alberta and the ... $3.39 million, three-year study to assess the potential effects ... "Nanotechnology is a very new and quickly developing field. ... solid scientific data upon which to base their regulatory ...
... In a discovery that rebuffs conventional scientific thinking, ... a novel way to block the activity of the ... found in children and young adults. In the ... , they report discovering and successfully testing a small ...
... 2009 Researchers at Ben-Gurion University of the Negev (BGU) ... may increase the possibility for diseases, including cancer., The findings ... Research ., The team of researchers from BGU,s National Institute ... for mutations in the genome of the mitochondria, a part ...
Cached Biology News:Canadian researchers set to study impact of nanomaterials on aquatic ecosystems 2GUMC discovery highlights new direction for drug discovery 2GUMC discovery highlights new direction for drug discovery 3Ben-Gurion U. researchers reveal connection between cancer and human evolution 2
propidium iodide *1.0 mg/mL solution in water*...
1 unit is sufficient for 1 caspase activity assay....
Applications: (+) Immunocytochemistry and immunohistochemistry...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: